Anti-Cancer/ Pharmaceutical Grade CAS 341031-54-7 Sunitinib

Anti-Cancer/ Pharmaceutical Grade CAS 341031-54-7 Sunitinib Malate

Email:kathelin@yccreate.com
Skype:live:kathelin_4
WhatsApp:+86-188 7222 0706

Attention:  Sold Only for scientific research purpose, shall not be used for human body.

Sunitinib Malate Description:
Biochem/physiol Actions
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.

Product Name: Sunitinib malate
Synonym: Sunitinib Malate; ;
Other names:N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt SU 011248 SU 11248 SU112248
CAS No.: 341031-54-7
 Molecular formula: C22H27FN4O2 · C4H6O5
 Molecular weight: 532.56
Content: 99%
Packing: 1KG/Package
Appearance: Orange yellow crystal
Grade: Pharmaceutical grade
Catagory: Pharmaceutical raw material
Storage:Store at -20°C

Sunitinib malate Use:
Sunitinib malate plays a role in the treatment by preventing cancer cells from getting blood and nutrients needed for growth. Clinical trials show that the medicine can delay the gastrointestinal stromal tumor's growth speed, and can reduce the size of renal cell cancer. Sunitinib malate is the first the new target drug to selectively according to multiple receptor tyrosine kinases, combined with the two function mechanism which terminate the formation of anti angiogenesis which provide blood to tumor cellss and the anti-tumor which directly attack tumor cells. It represents a new round of the advent of targeted therapies, not only directly attack the tumor, nor have conventional chemotherapy toxicity reaction.